10/26/2021 | SP | New Issue: Barclays sells $500,000 of 9.8% autocallable fixed-coupon notes on three stocks
|
2/20/2021 | SP | New Issue: BofA prices $4.45 million contingent income buffered autocalls on three stocks
|
1/16/2018 | DD | 21st Century Oncology plan of reorganization takes effect on Jan. 16
|
1/11/2018 | DD | 21st Century Oncology secures confirmation of plan of reorganization
|
12/11/2017 | DD | 21st Century Oncology deal tied to $123 million breach claim approved
|
11/21/2017 | DD | 21st Century Oncology reaches deal tied to $123 million breach claim
|
10/17/2017 | DD | 21st Century Oncology secures court approval of disclosure statement
|
9/20/2017 | DD | 21st Century Oncology wins precautionary 120-day exclusivity extension
|
9/6/2017 | DD | 21st Century Oncology eyes precautionary 120-day exclusivity extension
|
8/1/2017 | DD | 21st Century Oncology reports $16.74 million net loss for June period
|
6/20/2017 | BKDD | 21st Century Oncology granted final approval of $75 million DIP loan
|
6/15/2017 | DD | 21st Century Oncology five-member unsecured creditors committee named
|
6/2/2017 | BKCVDDEMHY | Prospect News reports zero new defaults for week of May 25 to May 31
|
5/26/2017 | DD | 21st Century Oncology wins interim access to $25 million of DIP loan
|
5/25/2017 | BKDDHY | 21st Century Oncology files bankruptcy, inks restructuring agreement
|
3/9/2017 | BKDDHY | 21st Century Oncology forbearance periods, unit’s loan extended again
|
2/2/2017 | BKDDHY | 21st Century Oncology forbearance agreements, unit’s loan extended
|
12/16/2016 | BKDDHY | 21st Century Oncology transaction agreement deadline pushed to Jan. 4
|
12/7/2016 | BKDDHY | 21st Century Oncology defaults on 11% notes, setting off loan default
|
11/4/2016 | BKCVDDEMHY | Prospect News reports five new defaults for Oct. 27-Nov. 2, S&P three
|
11/2/2016 | BKDDHY | S&P downgrades 21st Century
|
11/1/2016 | BKDDHY | 21st Century Oncology misses coupon on 11% senior notes, seeks talks
|
9/9/2016 | PP | 21st Century Oncology settles $25 million convertible preferreds sale
|
8/23/2016 | BKDDHY | 21st Century Oncology’s 10-K report contains going-concern warning
|
8/16/2016 | BKDDHY | 21st Century Oncology credit agreement and 11% notes defaults waived
|
6/13/2016 | BKDD | 21st Century Oncology secures credit agreement amendment and waiver
|
5/17/2016 | BKDDHY | 21st Century Oncology gets default notice from trustee for 11% notes
|
5/17/2016 | BKDDHY | S&P cuts 21st Century Oncology, debt
|
5/16/2016 | BKDDHY | 21st Century fails to file 10-K, could set off default on loan, notes
|
3/29/2016 | BKDDHY | S&P might cut 21st Century Oncology
|
4/28/2015 | HYLM | 21st Century Oncology gets consents to amend OnCure’s 11¾% notes
|
4/15/2015 | BKDDHY | S&P rates 21st Century loan B-, notes CCC
|
4/14/2015 | HY | 21st Century Oncology expected to sell $400 million eight-year notes via Morgan Stanley
|
4/13/2015 | HYLM | 21st Century Oncology starts tender, consent for OnCure’s 11¾% notes
|
4/13/2015 | CLHY | Market Commentary: Top Right, Mitel Networks break; Air Medical, Concordia Healthcare, Tekni-Plex revise deals
|
4/13/2015 | BK | Market Commentary: Top Right, Mitel Networks break; Air Medical, Concordia Healthcare, Tekni-Plex revise deals
|
3/19/2015 | BKBWHY | 21st Century Oncology cuts debt, ends year with $941 million debt
|
11/15/2014 | DD | Market Commentary: Energy takes a back seat in distressed world as 21st Century, Abengoa, Hertz bonds fall on news
|
11/14/2014 | HY | Market Commentary: Energy takes a back seat in distressed world as 21st Century, Abengoa, Hertz bonds fall on news
|
9/30/2014 | BKDD | S&P upgrades 21st Century, loans
|
9/26/2014 | HY | Market Commentary: Distressed bonds softer despite positive GDP; 21st Century pops on new financing; Cliffs down
|
9/26/2014 | DD | Market Commentary: Distressed bonds softer despite positive GDP; 21st Century pops on new financing; Cliffs down
|
9/26/2014 | BKCVDDEMIGPV | Market Commentary: High yield ends week in negative territory; GM Financial gains on S&P upgrade
|
9/26/2014 | HY | Market Commentary: High yield ends week in negative territory; GM Financial gains on S&P upgrade
|
9/26/2014 | BKDDHY | 21st Century Oncology gets $325 million investment, swaps restructuring
|
8/1/2014 | DD | S&P cuts 21st Century to CCC+
|
7/30/2014 | HY | Market Commentary: Mallinckrodt, upsized Paper Works price; Level 3 stays busy; First Data off after numbers
|
7/30/2014 | BKCVDDEMIGPV | Market Commentary: Mallinckrodt, upsized Paper Works price; Level 3 stays busy; First Data off after numbers
|
7/29/2014 | HY | Market Commentary: Upsized Level 3, other drive-bys pace $2.5 billion session; Windstream busy on REIT plan
|
7/29/2014 | BKCVDDEMIGPV | Market Commentary: Upsized Level 3, other drive-bys pace $2.5 billion session; Windstream busy on REIT plan
|
7/29/2014 | DDHY | 21st Century Oncology noteholders agree to support recapitalization
|
7/21/2014 | HY | Market Commentary: Primary stays quiet amid more fund outflows, awaits Transworld; Radiation Therapy still active
|
7/21/2014 | BKCVDDEMIGPV | Market Commentary: Primary stays quiet amid more fund outflows, awaits Transworld; Radiation Therapy still active
|
7/14/2014 | BK | S&P: 21st Century Oncology view negative
|
7/11/2014 | DD | Market Commentary: Caesars bonds seen active, Radiation Therapy off lows; Puerto Rico worries fluster funds
|
7/9/2014 | HY | Market Commentary: Drive-by parade continues with Summit Midstream, upsized Sinclair deals; new Calpine bonds busy
|
7/9/2014 | BKCVDDEMIGPV | Market Commentary: Drive-by parade continues with Summit Midstream, Sinclair deals; new Calpine bonds busy
|
7/8/2014 | HY | Market Commentary: Calpine, Walter, Magnetation drive by in $3.2 billion session; Radiation Therapy still sliding
|
7/8/2014 | BKCVDDEMIGPV | Market Commentary: Calpine, Walter, Magnetation drive by in $3.2 billion day; Radiation Therapy slides more
|
7/7/2014 | HY | Market Commentary: GM Financial drives by with $1.5 billion two-parter in otherwise quiet post-holiday session
|
5/27/2014 | HY | S&P: 21st Century Oncology view stable
|
5/16/2014 | PP | 21st Century to price IPO of 13,333,333 shares between $14.00, $16.00
|
2/11/2014 | PP | 21st Century Oncology to price initial public common stock offering
|